FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:853-855 August 26, 2004 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Spragg, R. G. PubMed Citation

Most therapies that fail to show benefit in well-conducted, randomized, controlled trials are abandoned by both clinical investigators and pharmaceutical companies. Treatment with exogenous surfactant for the acute respiratory distress syndrome (ARDS) appears to enjoy a different status. In this issue of the Journal, Spragg and coworkers (pages 884–892) present the results of two multicenter trials of recombinant surfactant therapy in ARDS, showing no significant difference in mortality between the groups of patients who received surfactant and those who received placebo. This report follows a number of other clinical studies, including a large, negative, multicenter, randomized, controlled trial that was . . . [Full Text of this Article]

Source Information

From the University Department of Surgical Sciences and the Department of Anaesthesia, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.

This article has been cited by other articles:

• Cepkova, M., Matthay, M. A. (2006). Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress Syndrome. J Intensive Care Med 21: 119-143 [Abstract]